leisure time -WSS

leisure time

author：comprehensive 2025-10-01 00:59:07 - browse：76

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Childhood cancer progress stalls for Black, Hispanic kids: Report

focus

WSS

Anthos stroke drug appears safer than common blood thinner

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Surge of respiratory disease in China has likely explanation

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Hospitals look to new technology to keep health care workers safe

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

knowledge

leisure time

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

How one medical school became remarkably diverse

Wegovy, Zepbound and weight loss drugs that preserve muscle

Activists slam private health insurers over coverage restrictions

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Anthos stroke drug appears safer than common blood thinner

Psychedelics group wrestles with new pharma identity

U.K. considers world's first use of meningitis vaccine to address gonorrhea

entertainment

Childhood cancer progress stalls for Black, Hispanic kids: Report

NYU radiologists take on the challenge of expensive MRI machines

Congress must reauthorize a committee to support older Americans

A daunting task: navigating dual Medicare, Medicaid eligibility

Congress must reauthorize a committee to support older Americans

Anthos stroke drug appears safer than common blood thinner

focus

hotspot

hotspot

leisure time